Background: The optimal period for discontinuing tafamidis in wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) patients based on cost-effectiveness is unknown.
Methods and results: A retrospective analysis of 80 tafamidis-treated ATTRwt-CM patients was conducted. The median follow up was 26.4 months; 17 patients permanently discontinued tafamidis, and 12 patients died after a median of 1.0 month following tafamidis discontinuation. Discontinuation was mainly due to non-cardiovascular hospitalization; deaths were mostly non-cardiovascular and occurred early after discontinuation.
Conclusions: The period from tafamidis discontinuation to death was shorter in ATTRwt-CM patients hospitalized for non-cardiovascular diseases. Discussions of the right period for discontinuation are needed.
{"title":"Discontinuation of Tafamidis in Wild-Type Transthyretin Amyloid Cardiomyopathy Patients.","authors":"Yuichi Baba, Yuri Ochi, Toru Kubo, Juri Kawaguchi, Naohito Yamasaki, Hiroaki Kitaoka","doi":"10.1253/circrep.CR-25-0181","DOIUrl":"10.1253/circrep.CR-25-0181","url":null,"abstract":"<p><strong>Background: </strong>The optimal period for discontinuing tafamidis in wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) patients based on cost-effectiveness is unknown.</p><p><strong>Methods and results: </strong>A retrospective analysis of 80 tafamidis-treated ATTRwt-CM patients was conducted. The median follow up was 26.4 months; 17 patients permanently discontinued tafamidis, and 12 patients died after a median of 1.0 month following tafamidis discontinuation. Discontinuation was mainly due to non-cardiovascular hospitalization; deaths were mostly non-cardiovascular and occurred early after discontinuation.</p><p><strong>Conclusions: </strong>The period from tafamidis discontinuation to death was shorter in ATTRwt-CM patients hospitalized for non-cardiovascular diseases. Discussions of the right period for discontinuation are needed.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 12","pages":"1301-1303"},"PeriodicalIF":1.1,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12688423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145728044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Electrode catheter placement into the coronary sinus (CS) is critical for electrophysiologic studies. Although central venous approaches (e.g., internal jugular or subclavian) are well documented, peripheral venous approaches like the cubital vein are not. This study evaluated the feasibility and safety of CS catheter placement via the right cubital vein during atrial fibrillation (AF) ablation.
Methods and results: Of 1,363 consecutive patients who underwent first-time AF ablation at Sakurabashi Watanabe Advanced Healthcare Hospital between January 2019 and December 2021, 1,274 underwent at least 1 right cubital vein puncture attempt. The success rate, causes of failure, and complications were analyzed. CS catheters were successfully placed via the right cubital vein in 1,214 (95.3%) patients, whereas placements were unsuccessful in 60 (4.7%) patients. Although older patients were more likely to experience unsuccessful placements, there were no significant differences in other baseline characteristics between the 2 groups. Unsuccessful placements were attributed to failure in venipuncture or sheath insertion (n=49) and failure to advance the CS catheter through the vein (n=11). No major complications were reported.
Conclusions: CS catheter placement via the right cubital vein demonstrated high feasibility and safety, with a 95% success rate and minimal complications. This approach offers a practical and technically straightforward alternative for placing CS catheters, particularly in patients with adequate vein development.
{"title":"Placement of the Coronary Sinus Catheter via the Right Cubital Vein During Atrial Fibrillation Ablation.","authors":"Kohei Iwasa, Masato Okada, Koji Tanaka, Yuko Hirao, Naoko Miyazaki, Heitaro Watanabe, Yoshitaka Iwanaga, Atsunori Okamura, Yasushi Sakata, Nobuaki Tanaka","doi":"10.1253/circrep.CR-25-0187","DOIUrl":"10.1253/circrep.CR-25-0187","url":null,"abstract":"<p><strong>Background: </strong>Electrode catheter placement into the coronary sinus (CS) is critical for electrophysiologic studies. Although central venous approaches (e.g., internal jugular or subclavian) are well documented, peripheral venous approaches like the cubital vein are not. This study evaluated the feasibility and safety of CS catheter placement via the right cubital vein during atrial fibrillation (AF) ablation.</p><p><strong>Methods and results: </strong>Of 1,363 consecutive patients who underwent first-time AF ablation at Sakurabashi Watanabe Advanced Healthcare Hospital between January 2019 and December 2021, 1,274 underwent at least 1 right cubital vein puncture attempt. The success rate, causes of failure, and complications were analyzed. CS catheters were successfully placed via the right cubital vein in 1,214 (95.3%) patients, whereas placements were unsuccessful in 60 (4.7%) patients. Although older patients were more likely to experience unsuccessful placements, there were no significant differences in other baseline characteristics between the 2 groups. Unsuccessful placements were attributed to failure in venipuncture or sheath insertion (n=49) and failure to advance the CS catheter through the vein (n=11). No major complications were reported.</p><p><strong>Conclusions: </strong>CS catheter placement via the right cubital vein demonstrated high feasibility and safety, with a 95% success rate and minimal complications. This approach offers a practical and technically straightforward alternative for placing CS catheters, particularly in patients with adequate vein development.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 12","pages":"1181-1189"},"PeriodicalIF":1.1,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12688425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145728026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Electrical storm (ES) is defined as a condition in which ventricular tachycardia (VT) or ventricular fibrillation (VF) episodes requiring electrical shock or implantable cardioverter-defibrillator (ICD) shocks occur ≥3 times within 24 h. It is a life-threatening condition, and treatment options include antiarrhythmic drugs, sedation, circulatory support, and catheter ablation. Sedation is conventionally performed for repeated electrical shocks; however, evidence for its effectiveness in ES suppression remains limited. This scoping review aimed to assess whether the use of sedatives is beneficial for ES suppression.
Methods and results: This scoping review followed the PRISMA extension for scoping reviews (PRISMA-ScR) guidelines. Three online databases were searched to identify studies published from the inception of each database until September 18, 2024. To date, no randomized or quasi-randomized controlled trials or observational analytical studies have met the inclusion criteria for the use of sedation in patients with ES.
Conclusions: This scoping review underscores the need for high-quality studies to enhance the level of evidence and bridge knowledge gaps, ultimately aiming to shift the care paradigm for patients with ES.
{"title":"Should Sedative Administration Be Recommended as an Antiarrhythmic Therapy to Suppress Ventricular Fibrillation and Ventricular Tachycardia in Patients With Electrical Storm? - A Scoping Review.","authors":"Takayuki Kitai, Tetsuma Kawaji, Yukio Hosaka, Mutsuko Sangawa, Hiroki Shiomi, Eiji Hiraoka, Kazuo Sakamoto, Kenichi Iijima, Masashi Yokose, Teruo Noguchi, Hiroshi Takahashi, Tetsuya Matoba, Migaku Kikuchi, Yoshio Tahara, Hiroshi Nonogi, Toshikazu Funazaki","doi":"10.1253/circrep.CR-25-0176","DOIUrl":"10.1253/circrep.CR-25-0176","url":null,"abstract":"<p><strong>Background: </strong>Electrical storm (ES) is defined as a condition in which ventricular tachycardia (VT) or ventricular fibrillation (VF) episodes requiring electrical shock or implantable cardioverter-defibrillator (ICD) shocks occur ≥3 times within 24 h. It is a life-threatening condition, and treatment options include antiarrhythmic drugs, sedation, circulatory support, and catheter ablation. Sedation is conventionally performed for repeated electrical shocks; however, evidence for its effectiveness in ES suppression remains limited. This scoping review aimed to assess whether the use of sedatives is beneficial for ES suppression.</p><p><strong>Methods and results: </strong>This scoping review followed the PRISMA extension for scoping reviews (PRISMA-ScR) guidelines. Three online databases were searched to identify studies published from the inception of each database until September 18, 2024. To date, no randomized or quasi-randomized controlled trials or observational analytical studies have met the inclusion criteria for the use of sedation in patients with ES.</p><p><strong>Conclusions: </strong>This scoping review underscores the need for high-quality studies to enhance the level of evidence and bridge knowledge gaps, ultimately aiming to shift the care paradigm for patients with ES.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 12","pages":"1149-1153"},"PeriodicalIF":1.1,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12688421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145727445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: We developed the SaFIS, a structured self-administered food intake survey for patients with cardiovascular diseases needing dietary improvements.
Methods and results: The SaFIS comprised questions on 31 items, including staple foods (7 items) and food ingredients (24 items), based on the foods recommended by the Japanese Atherosclerosis Society for the Prevention of Arteriosclerotic Disease. To evaluate reproducibility, SaFIS was administered twice with a 1-month interval using the intraclass correlation coefficient (ICC [1,1]). Validity was assessed by comparing energy and nutrient content from a weighed dietary record (WDR) with the first SaFIS survey using Bland-Altman plots. Reproducibility values were energy (ICC 0.90, 95% confidence interval: 0.80-0.95), protein (0.90, 0.80-0.95), fat (0.76, 0.54-0.88), saturated fatty acids (0.78, 0.58-0.89), monounsaturated fatty acids (0.76, 0.56-0.88), polyunsaturated fatty acids (0.82, 0.66-0.91), carbohydrates (0.89, 0.79-0.95), and dietary fiber (0.86, 0.71-0.93). Bland-Altman values indicated SaFIS-based energy, protein, carbohydrate, monounsaturated fatty acids, and dietary fiber were 67.2 kJ, 5.7 g, 3.9 g, 0.5 g, and 1.8 g greater than WDR-based values, respectively. SaFIS-based fat, saturated, and polyunsaturated fatty acid values were 0.7 g, 1.3 g, and 0.39 g less than WDR-based values, respectively.
Conclusions: SaFIS demonstrated high reproducibility and validity with clinical potential. Subsequent introduction to digital health from the usability perspective is planned.
{"title":"Reproducibility and Validity of a Food Intake Survey Developed for Implementation via Digital Health for Patients With or at Risk for Cardiovascular Disease.","authors":"Daisuke Moriyama, Takuji Adachi, Kuya Funaki, Hironobu Ashikawa, Ken Harada, Sumio Yamada","doi":"10.1253/circrep.CR-25-0032","DOIUrl":"10.1253/circrep.CR-25-0032","url":null,"abstract":"<p><strong>Background: </strong>We developed the SaFIS, a structured self-administered food intake survey for patients with cardiovascular diseases needing dietary improvements.</p><p><strong>Methods and results: </strong>The SaFIS comprised questions on 31 items, including staple foods (7 items) and food ingredients (24 items), based on the foods recommended by the Japanese Atherosclerosis Society for the Prevention of Arteriosclerotic Disease. To evaluate reproducibility, SaFIS was administered twice with a 1-month interval using the intraclass correlation coefficient (ICC [1,1]). Validity was assessed by comparing energy and nutrient content from a weighed dietary record (WDR) with the first SaFIS survey using Bland-Altman plots. Reproducibility values were energy (ICC 0.90, 95% confidence interval: 0.80-0.95), protein (0.90, 0.80-0.95), fat (0.76, 0.54-0.88), saturated fatty acids (0.78, 0.58-0.89), monounsaturated fatty acids (0.76, 0.56-0.88), polyunsaturated fatty acids (0.82, 0.66-0.91), carbohydrates (0.89, 0.79-0.95), and dietary fiber (0.86, 0.71-0.93). Bland-Altman values indicated SaFIS-based energy, protein, carbohydrate, monounsaturated fatty acids, and dietary fiber were 67.2 kJ, 5.7 g, 3.9 g, 0.5 g, and 1.8 g greater than WDR-based values, respectively. SaFIS-based fat, saturated, and polyunsaturated fatty acid values were 0.7 g, 1.3 g, and 0.39 g less than WDR-based values, respectively.</p><p><strong>Conclusions: </strong>SaFIS demonstrated high reproducibility and validity with clinical potential. Subsequent introduction to digital health from the usability perspective is planned.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 11","pages":"1109-1115"},"PeriodicalIF":1.1,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12597241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145491327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-04eCollection Date: 2025-12-10DOI: 10.1253/circrep.CR-25-0164
Yukio Shiina, Atsuhito Fukushima, Migaku Kikuchi
Background: This study retrospectively evaluated the safety of resuscitation training during the Coronavirus Disease 2019 (COVID-19) pandemic under Japan Resuscitation Council (JRC) guidance.
Methods and results: From 2018 to 2024, all participating staff were monitored by the Infection Prevention and Control Center. Although learner numbers declined in 2020, training sessions increased, and numbers returned to prepandemic levels. The Resuscitation Quality Improvement program enabled flexible, contactless training, further boosting participation. Notably, no COVID-19 cases were linked to training sessions.
Conclusions: These findings demonstrate that resuscitation training can be conducted safely by adhering to JRC guidance, even during a public health crisis.
{"title":"Resuscitation Training Amid the Coronavirus Disease 2019 Pandemic - A Safe Approach.","authors":"Yukio Shiina, Atsuhito Fukushima, Migaku Kikuchi","doi":"10.1253/circrep.CR-25-0164","DOIUrl":"https://doi.org/10.1253/circrep.CR-25-0164","url":null,"abstract":"<p><strong>Background: </strong>This study retrospectively evaluated the safety of resuscitation training during the Coronavirus Disease 2019 (COVID-19) pandemic under Japan Resuscitation Council (JRC) guidance.</p><p><strong>Methods and results: </strong>From 2018 to 2024, all participating staff were monitored by the Infection Prevention and Control Center. Although learner numbers declined in 2020, training sessions increased, and numbers returned to prepandemic levels. The Resuscitation Quality Improvement program enabled flexible, contactless training, further boosting participation. Notably, no COVID-19 cases were linked to training sessions.</p><p><strong>Conclusions: </strong>These findings demonstrate that resuscitation training can be conducted safely by adhering to JRC guidance, even during a public health crisis.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 12","pages":"1298-1300"},"PeriodicalIF":1.1,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12688420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145727166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01eCollection Date: 2025-11-10DOI: 10.1253/circrep.CR-25-0203
Junichi Yokota
{"title":"Exploring the Optimal Amount of Cardiac Rehabilitation During Hospitalization for Recovery of Activities of Daily Living.","authors":"Junichi Yokota","doi":"10.1253/circrep.CR-25-0203","DOIUrl":"10.1253/circrep.CR-25-0203","url":null,"abstract":"","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 11","pages":"1060-1061"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12597235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145491161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Decline or inadequate recovery of activities of daily living (ADL) during hospitalization is crucial for clinical prognosis. In this study we investigated the relationship between cardiac rehabilitation (CR) and ADL recovery in patients with cardiovascular disease (CVD), with the aim of exploring associations that may contribute to the development of rehabilitation interventions.
Methods and results: This study analyzed consecutive patients hospitalized with CVD. ADL was assessed using the Barthel index (BI) at the commencement of rehabilitation and discharge. As the outcome measure for ADL, relative functional gain: BI effectiveness, calculated as (discharge BI - initial BI) / (100 - initial BI), was adopted in order to compensate ceiling effect of BI. BI effectiveness ≥0.5 defined the ADL recovery group, while <0.5 defined the ADL non-recovery group. Of the 2,938 patients screened, 1,582 (median age 79 years, male 59%) were included after exclusions. The ADL recovery group consisted of 1,162 patients, the ADL non-recovery group, 420 patients. Between-group comparisons and multivariate regression analysis identified age and initial BI as highly significant ADL recovery determinants. Recursive partitioning analysis showed CR volumes of ≥75 min/day for patients ≥75 years and ≥45 min/day for those <75 years with lower initial BI were associated with ADL recovery. These CR volumes also reduced the institutionalization odds ratios (OR=0.42 and OR=0.34, P<0.001) compared to CR volumes <45 min/day.
Conclusions: CR volume was associated with ADL recovery, especially for older patients with low baseline function at admission. Optimizing CR volume based on patient background and condition may contribute to enhance ADL recovery and improved clinical prognosis.
{"title":"Relationship Between Cardiac Rehabilitation and Recovery From Decline in Activities of Daily Living in Patients Hospitalized With Cardiovascular Disease.","authors":"Masami Kimura, Masataka Nakano, Chie Shiraishi, Shota Onoda, Takashi Amari, Kento Ihara, Kentaro Watanabe, Sayuri Tanaka, Takaaki Isshiki","doi":"10.1253/circrep.CR-25-0024","DOIUrl":"10.1253/circrep.CR-25-0024","url":null,"abstract":"<p><strong>Background: </strong>Decline or inadequate recovery of activities of daily living (ADL) during hospitalization is crucial for clinical prognosis. In this study we investigated the relationship between cardiac rehabilitation (CR) and ADL recovery in patients with cardiovascular disease (CVD), with the aim of exploring associations that may contribute to the development of rehabilitation interventions.</p><p><strong>Methods and results: </strong>This study analyzed consecutive patients hospitalized with CVD. ADL was assessed using the Barthel index (BI) at the commencement of rehabilitation and discharge. As the outcome measure for ADL, relative functional gain: BI effectiveness, calculated as (discharge BI - initial BI) / (100 - initial BI), was adopted in order to compensate ceiling effect of BI. BI effectiveness ≥0.5 defined the ADL recovery group, while <0.5 defined the ADL non-recovery group. Of the 2,938 patients screened, 1,582 (median age 79 years, male 59%) were included after exclusions. The ADL recovery group consisted of 1,162 patients, the ADL non-recovery group, 420 patients. Between-group comparisons and multivariate regression analysis identified age and initial BI as highly significant ADL recovery determinants. Recursive partitioning analysis showed CR volumes of ≥75 min/day for patients ≥75 years and ≥45 min/day for those <75 years with lower initial BI were associated with ADL recovery. These CR volumes also reduced the institutionalization odds ratios (OR=0.42 and OR=0.34, P<0.001) compared to CR volumes <45 min/day.</p><p><strong>Conclusions: </strong>CR volume was associated with ADL recovery, especially for older patients with low baseline function at admission. Optimizing CR volume based on patient background and condition may contribute to enhance ADL recovery and improved clinical prognosis.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 11","pages":"1051-1059"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12597247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145491198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: There is a substantial risk of slow flow during percutaneous coronary intervention (PCI) for the culprit lesion in acute myocardial infarction (AMI), which can lead to adverse outcomes. We hypothesized that single-step long balloon inflation during stent deployment was associated with a more favorable final Thrombolysis in Myocardial Infarction (TIMI) flow grade. This retrospective study aimed to compare both the final TIMI flow grade and the delta TIMI flow grade in intravascular ultrasound (IVUS)-guided PCI for AMI between patients with long balloon inflation and those with conventional inflation.
Methods and results: Long inflation was defined as single-step inflation ≥60 s at stent deployment. The primary endpoints were achievement of the final TIMI flow grade 3 and the delta TIMI flow grade, defined as the difference between the initial and final grades. We analyzed 336 AMI patients with attenuation plaque on IVUS, dividing them into a long inflation group (n=50) and a conventional inflation group (n=286). Despite a significantly higher TIMI thrombus grade in the long inflation group (P<0.001), the rate of the final TIMI 3 flow was similar (90% vs. 88.5%; P=1.00). However, the delta TIMI flow grade was significantly greater in the long inflation group (P=0.028).
Conclusions: Single-step long balloon inflation may be a simple and feasible method to achieve optimal final TIMI flow in IVUS-guided PCI for AMI.
{"title":"Long Inflation at Stent Deployment in Intravascular Ultrasound-Guided Percutaneous Coronary Intervention for Acute Myocardial Infarction.","authors":"Yusuke Watanabe, Kenichi Sakakura, Hiroyuki Jinnouchi, Yousuke Taniguchi, Kei Yamamoto, Masaru Seguchi, Takunori Tsukui, Taku Kasahara, Masashi Hatori, Shun Ishibashi, Hideo Fujita","doi":"10.1253/circrep.CR-25-0141","DOIUrl":"10.1253/circrep.CR-25-0141","url":null,"abstract":"<p><strong>Background: </strong>There is a substantial risk of slow flow during percutaneous coronary intervention (PCI) for the culprit lesion in acute myocardial infarction (AMI), which can lead to adverse outcomes. We hypothesized that single-step long balloon inflation during stent deployment was associated with a more favorable final Thrombolysis in Myocardial Infarction (TIMI) flow grade. This retrospective study aimed to compare both the final TIMI flow grade and the delta TIMI flow grade in intravascular ultrasound (IVUS)-guided PCI for AMI between patients with long balloon inflation and those with conventional inflation.</p><p><strong>Methods and results: </strong>Long inflation was defined as single-step inflation ≥60 s at stent deployment. The primary endpoints were achievement of the final TIMI flow grade 3 and the delta TIMI flow grade, defined as the difference between the initial and final grades. We analyzed 336 AMI patients with attenuation plaque on IVUS, dividing them into a long inflation group (n=50) and a conventional inflation group (n=286). Despite a significantly higher TIMI thrombus grade in the long inflation group (P<0.001), the rate of the final TIMI 3 flow was similar (90% vs. 88.5%; P=1.00). However, the delta TIMI flow grade was significantly greater in the long inflation group (P=0.028).</p><p><strong>Conclusions: </strong>Single-step long balloon inflation may be a simple and feasible method to achieve optimal final TIMI flow in IVUS-guided PCI for AMI.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 12","pages":"1230-1239"},"PeriodicalIF":1.1,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12688430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145727974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Malnutrition is a significant prognostic factor in chronic heart failure (CHF), particularly among older adults. The geriatric nutritional risk index (GNRI) is a screening tool for assessing malnutrition in this population. Although low GNRI is associated with increased deaths of patients with HF, the prognostic impact of longitudinal GNRI changes in malnourished patients remains unclear.
Methods and results: This post-hoc analysis of the KUNIUMI registry chronic cohort, a prospective observational study of patients with pre-HF/HF, assessed GNRI at baseline and 1-year follow-up. The annual GNRI change (∆GNRI) was calculated, and its association with all-cause death in malnourished patients was analyzed. The primary outcome was all-cause death, with a 2-year follow-up after the initial 1-year assessment. Among 1,242 patients (mean age: 74.4±10.9 years), 19.8% had low GNRI (<92). All-cause death was significantly higher in patients with low GNRI than in those with high GNRI (30.1% vs. 7.1%; P<0.001). In patients with low GNRI, multivariable Cox regression showed a significant association between ∆GNRI and death (hazard ratio: 0.94; 95% confidence interval: 0.91-0.96; P<0.001). Multiple linear regression indicated that nutritional counseling positively influenced ∆GNRI, but HF severity was not significantly associated.
Conclusions: ∆GNRI is a significant prognostic indicator in malnourished patients with pre-HF/HF. Serial GNRI assessments may improve risk stratification and guide nutritional interventions.
{"title":"Prognostic Impact of Annual Changes in the Geriatric Nutritional Risk Index in Malnourished Patients With Heart Failure.","authors":"Tatsuya Kitagawa, Wataru Fujimoto, Makoto Takemoto, Koji Kuroda, Soichiro Yamashita, Junichi Imanishi, Masamichi Iwasaki, Takafumi Todoroki, Masanori Okuda, Manabu Nagao, Akihide Konishi, Ryuji Toh, Kunihiro Nishimura, Masakazu Shinohara, Hiromasa Otake","doi":"10.1253/circrep.CR-25-0177","DOIUrl":"10.1253/circrep.CR-25-0177","url":null,"abstract":"<p><strong>Background: </strong>Malnutrition is a significant prognostic factor in chronic heart failure (CHF), particularly among older adults. The geriatric nutritional risk index (GNRI) is a screening tool for assessing malnutrition in this population. Although low GNRI is associated with increased deaths of patients with HF, the prognostic impact of longitudinal GNRI changes in malnourished patients remains unclear.</p><p><strong>Methods and results: </strong>This post-hoc analysis of the KUNIUMI registry chronic cohort, a prospective observational study of patients with pre-HF/HF, assessed GNRI at baseline and 1-year follow-up. The annual GNRI change (∆GNRI) was calculated, and its association with all-cause death in malnourished patients was analyzed. The primary outcome was all-cause death, with a 2-year follow-up after the initial 1-year assessment. Among 1,242 patients (mean age: 74.4±10.9 years), 19.8% had low GNRI (<92). All-cause death was significantly higher in patients with low GNRI than in those with high GNRI (30.1% vs. 7.1%; P<0.001). In patients with low GNRI, multivariable Cox regression showed a significant association between ∆GNRI and death (hazard ratio: 0.94; 95% confidence interval: 0.91-0.96; P<0.001). Multiple linear regression indicated that nutritional counseling positively influenced ∆GNRI, but HF severity was not significantly associated.</p><p><strong>Conclusions: </strong>∆GNRI is a significant prognostic indicator in malnourished patients with pre-HF/HF. Serial GNRI assessments may improve risk stratification and guide nutritional interventions.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 12","pages":"1211-1221"},"PeriodicalIF":1.1,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12688437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145727139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Intravenous atropine is widely recommended as the first-line treatment for symptomatic bradycardia, but because the optimal initial dose remains uncertain, the aim of this scoping review was to examine the existing literature on the efficacy and safety of intravenous atropine at specific doses in adult patients with symptomatic bradycardia and to identify gaps in evidence. A systematic search of 4 databases (PubMed, CENTRAL, Web of Science, and Ichushi-Web) was conducted from inception to December 16, 2024. Studies were included if they reported administration of a specified dose of atropine in adult patients, regardless of study design. No randomized controlled trials directly comparing 0.5 mg vs. 1.0 mg were found. A total of 19 studies were included and categorized into groups based on initial atropine dose: low (<0.5 mg), moderate (0.5 mg ≤ dose <1.0 mg), high (≥1.0 mg), and those spanning multiple categories. No consistent relationship was found between atropine dose and clinical outcomes, such as heart rate response or adverse effects. None of the moderate-dose studies reported worsening bradycardia. Moderate-dose atropine could be safe, and the current practice of using 0.5 mg as an initial dose in Japan, where 0.5 mg/mL prefilled syringes are commercially available, appears clinically reasonable. However, in the absence of high-quality comparative data, future research should apply rigorous study designs to determine the optimal atropine dose in emergency care settings.
静脉注射阿托品被广泛推荐作为对症性心动过缓的一线治疗,但由于最佳初始剂量仍不确定,本综述的目的是检查关于特定剂量静脉注射阿托品治疗对症性心动过缓成人患者的有效性和安全性的现有文献,并找出证据中的空白。系统检索了4个数据库(PubMed, CENTRAL, Web of Science, Ichushi-Web),从成立到2024年12月16日。无论研究设计如何,只要报告成人患者使用特定剂量的阿托品,就纳入研究。没有发现直接比较0.5 mg和1.0 mg的随机对照试验。共纳入19项研究,并根据阿托品的初始剂量分为两组:低(
{"title":"Initial Dose of Intravenous Atropine for Patients With Symptomatic Bradycardia - A Scoping Review.","authors":"Masashi Yokose, Mutsuko Sangawa, Hiroki Shiomi, Kazuo Sakamoto, Kenichi Iijima, Tetsuma Kawaji, Takayuki Kitai, Yukio Hosaka, Eiji Hiraoka, Teruo Noguchi, Hiroshi Takahashi, Tetsuya Matoba, Migaku Kikuchi, Yoshio Tahara, Hiroshi Nonogi, Toshikazu Funazaki","doi":"10.1253/circrep.CR-25-0169","DOIUrl":"10.1253/circrep.CR-25-0169","url":null,"abstract":"<p><p>Intravenous atropine is widely recommended as the first-line treatment for symptomatic bradycardia, but because the optimal initial dose remains uncertain, the aim of this scoping review was to examine the existing literature on the efficacy and safety of intravenous atropine at specific doses in adult patients with symptomatic bradycardia and to identify gaps in evidence. A systematic search of 4 databases (PubMed, CENTRAL, Web of Science, and Ichushi-Web) was conducted from inception to December 16, 2024. Studies were included if they reported administration of a specified dose of atropine in adult patients, regardless of study design. No randomized controlled trials directly comparing 0.5 mg vs. 1.0 mg were found. A total of 19 studies were included and categorized into groups based on initial atropine dose: low (<0.5 mg), moderate (0.5 mg ≤ dose <1.0 mg), high (≥1.0 mg), and those spanning multiple categories. No consistent relationship was found between atropine dose and clinical outcomes, such as heart rate response or adverse effects. None of the moderate-dose studies reported worsening bradycardia. Moderate-dose atropine could be safe, and the current practice of using 0.5 mg as an initial dose in Japan, where 0.5 mg/mL prefilled syringes are commercially available, appears clinically reasonable. However, in the absence of high-quality comparative data, future research should apply rigorous study designs to determine the optimal atropine dose in emergency care settings.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 11","pages":"1044-1050"},"PeriodicalIF":1.1,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12597395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145491126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}